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http://www.lipidworld.com/content/13/1/36RESEARCH Open AccessLactobacillus gasseri SBT2055 reduces postprandial
and fasting serum non-esterified fatty acid levels
in Japanese hypertriacylglycerolemic subjects
Akihiro Ogawa1,2, Yukio Kadooka2, Ken Kato2, Bungo Shirouchi1 and Masao Sato1*Abstract
Background: Lactobacillus gasseri SBT2055 (LG2055) inhibits dietary fat absorption in rats and exerts preventive
effects on abdominal adiposity in rats and humans. The present study aimed to evaluate the effects of LG2055 on
postprandial serum lipid responses in Japanese subjects with hypertriacylglycerolemia after the intake of oral
fat-loading test (OFLT) meals.
Methods: We conducted a single-blind, placebo-controlled, within-subject, repeated-measure intervention trial.
Twenty subjects initially ingested the fermented milk (FM) without LG2055 for 4 weeks (control FM period), followed
by a 4-week washout period, and then consumed FM containing LG2055 for 4 weeks (active FM period). The
subjects were asked to consume FM at 200 g/day. At the end of each 4-week period, an 8-h OFLT was conducted.
Blood samples were collected at fasting and every hour for 8 h after OFLT meal intake. Thereafter, postprandial
serum non-esterified fatty acid (NEFA) and triacylglycerol (TAG) levels and fasting blood parameters were measured.
Results: The OFLT showed that the postprandial serum NEFA levels from 120 to 480 min and the postprandial
serum TAG level at 120 min in the active FM period were significantly (P < 0.05) lower than those in the control FM
period. The fasting serum NEFA level in the active FM period significantly (P < 0.001) decreased at week 4 from the
initial period compared with the control FM period.
Conclusions: The consumption of probiotic LG2055 reduced postprandial and fasting serum NEFA levels,
suggesting its possible contribution to the reduction of the risk for obesity and type 2 diabetes mellitus.
Trial registration: UMIN000011605
Keywords: Probiotics, Lactobacillus gasseri SBT2055, Oral fat-loading test, Postprandial lipid response, Fermented
milk products, Non-esterified fatty acid, TriacylglycerolBackground
Lactobacillus gasseri SBT2055 (LG2055), a probiotic lac-
tic acid bacterium that originates from the human intes-
tine [1,2] and has the ability to improve the intestinal
environment [3], was demonstrated to diminish lymph-
atic triacylglycerol (TAG) transport and increase fecal
fatty acids excretion, thereby inhibiting intestinal fat ab-
sorption [4], and to have anti-obesity effects in rats
[4-6], mice [7], and humans [8,9]. In our previous* Correspondence: masaos@agr.kyushu-u.ac.jp
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unless otherwise stated.clinical study [8,9], Japanese adults with obese tenden-
cies consumed fermented milk containing LG2055 at
200 g/day for 12 weeks and consequently exhibited sig-
nificantly reduced visceral fat areas, body weight, body
mass index (BMI), and waist and hip circumferences.
However, the effects of LG2055 on postprandial lipid
metabolism remain to be investigated.
Several possible factors affect postprandial lipid me-
tabolism. Energy intake reduction by suppression of diet-
ary fat absorption is a strategy for the regulation of
postprandial lipid metabolism. Orlistat, which is a strong
lipase inhibitor [10] approved by the US Food and Drug
Administration as a medication for long-term obesity
treatment [11], improved postprandial lipid metabolismLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of fat absorption [12]. Functional food components were
also shown to have a suppressive effect on fat absorption
and an anti-obesity effect. For example, mannooligosac-
charide (MOS) supplementation reduced fat absorption
[13,14], leading to body weight and visceral fat loss after
12 weeks in humans [15,16]. The inhibition of dietary fat
absorption by MOS was more moderate than that by
orlistat; orlistat administration reduced fat absorption by
approximately 30% [17], whereas MOS intake signifi-
cantly lowered fat utilization by approximately 2% [14].
However, to our knowledge, no intervention study has
been conducted to examine postprandial lipid metabol-
ism using probiotics.
In this study, we examined the effects of the probiotic
LG2055 on postprandial serum lipid responses in Japanese
subjects with hypertriacylglycerolemia, referring to an
oral fat-loading test (OFLT) study of Lopez et al. [18].
Methods
Subjects
Twenty adults, whose background characteristics are
summarized in Table 1, were enrolled in this study. We
recruited adults who had hypertriacylglycerolemia with
fasting TAG levels higher than 200 mg/dl [19] and nor-
mal blood fasting glucose levels lower than 110 mg/dl.Table 1 Baseline characteristics of the study subjects
Parameters
Number of subjects 20
Male 15
Female 5
Age (years) 51.1 (6.6)







Systolic blood pressure (mm Hg) 111.0 (11)
Diastolic blood pressure (mm Hg) 73.0 (9)
Pulse rate (beats/min) 69.0 (8)
TAG (mg/dl) 277.0 (57)
Total cholesterol (mg/dl) 215.0 (41)
NEFA (mEq/l) 0.58 (0.22)
Glucose (mg/dl) 90.0 (7)
Insulin (μU/ml) 7.3 (2.1)
Abbreviations: BMI body mass index, TAG triacylglycerol, NEFA non-esterified
fatty acid.
The data are expressed as mean (SD) values.Those who had severe internal organ disorders, including
coronary heart disease, renal impairment, hypothyroidism,
or liver dysfunction, and hypersensitivity to dairy products
were excluded. None of the subjects used tobacco, con-
sumed special health-promoting foods, or took medication
known to alter gastric emptying, lipoprotein metabolism,
insulin secretion, or insulin activity.
Study design
This study was performed as a single-blind, placebo-
controlled, within-subject, repeated-measure interven-
tion trial. The crossover design was not adopted because
it was possible that LG2055 survived in the intestinal
tract after the washout period [3]. In a previous study,
LG2055 was detected in a fecal sample even 90 days after
LG2055 administration was discontinued [3]. Therefore,
we set the placebo treatment period before the LG2055
treatment period. This study was conducted according to
the guidelines established in the Declaration of Helsinki
and the Ethical Guidelines for Epidemiological Research
(Ministry of Health, Labour and Welfare of Japan), and
all procedures involving human subjects/patients were
approved by the institutional review board of Fukuda
Clinic (Yodogawa-ku, Osaka, Japan) before initiation of
the study. All the subjects provided written informed
consent before participation in the study. This study
was conducted from November 2011 to February 2012 by
a contract research organization, Soiken Inc. (Toyonaka,
Osaka, Japan). The clinical trial was registered in the
University Hospital Medical Information Network Clinical
Trials (No. UMIN000011605).
Preparation of the test fermented milk
Lactobacillus gasseri SBT2055 (LG2055) was provided in
fermented milk (FM). Two types of FM were prepared
as previously reported [8], that is, active FM containing
LG2055 and control FM lacking LG2055. The active FM
was prepared with lactic acid bacteria starter cultures
(Streptococcus thermophilus and Lactobacillus delbrueckii
spp. bulgaricus) that are commonly used for conventional
yogurt production and viable cells of LG2055. A FM mix-
ture consisting of approximately 11% skim milk powder
and a small amount of flavoring, agar, and sucralose as
artificial sweetener with a zero-energy value was inocu-
lated with the yogurt starter cultures and LG2055 cells
and then cultured at 40°C for 3.5−4 h. The viable cell
count of LG2055 was approximately 5 × 1010 cfu/100 g of
FM on the initial day. The control FM was prepared in
the same manner except that LG2055 cells were not
added. These FM preparations were equivalent in en-
ergy (146.4 kJ), protein (3.7 g), fat (0.1 g), carbohydrate
(4.9 g), and sodium content (41 mg) per 100 g and were
indistinguishable in taste. The test FM preparations
were kept in cold storage and delivered weekly.
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The subjects initially consumed the control FM for 4
weeks, followed by a 4-week washout period, and then
the subjects consumed the active FM for 4 weeks. Initi-
ation of the consumption of either the control or active
FM was designated as week 0 (W0). While maintaining
their habitual mode of living including diet and exercise,
the subjects consumed FM at 200 g/day as two portions
of 100 g each after breakfast and dinner.
Measurements of body weight, waist circumference,
blood pressure, pulse rate, and fasting blood parameters
and an interview with a physician were performed at the
beginning and end of each 4-week intake period (W0
and W4, respectively). At the end of each 4-week intake
period, an 8-h OFLT was performed. Each subject made
a daily record of the amount of test FM intake, alcohol
consumed, and medicine taken. A detailed dietary record
was also made by the subjects for three consecutive days
before each time point (W0 and W4). Information re-
garding subjective symptoms such as headache, nausea,
and abdominal pain was collected through an interview
with a physician at each time point (W0 and W4).
Oral fat-loading test
The subjects stayed at the same hotel on the day prior
to the OFLT and consumed a dinner with an energy
content of approximately 3 765.6 kJ between 19:30 and
20:00 hours, after which the subjects were not allowed
to eat and drink anything except water until the begin-
ning of the OFLT. The total energy provided by the
OFLT meals was 2 468.6 kJ, with a macronutrient profile
of 72% fat, 24% carbohydrate, and 4% protein, which was
in accordance with the methods of Lopez et al. [18]. The
meals consisted of 200 g of corn cream potage (Nagoya
Seiraku Co., Ltd., Nagoya, Japan), 37 g of salt-free butter
(Megmilk Snow Brand Co., Ltd., Tokyo, Japan), and 29 g
of meal test C (Saraya Co., Ltd., Osaka, Japan); total
amount of fat in the meals was 47.2 g. After a 12-h fasting
period, the subjects ingested the OFLT meals and con-
comitantly consumed the test FM. Blood samples were
collected from the median cubital, basilic, or cephalic vein
before intake of the OFLT meals (fasting) and each hour
after 8 h of OFLT meal intake.
Blood sample analyses
The blood samples were centrifuged at 1 730 × g for 10
min at 4°C, and the supernatant was stored at a tem-
perature lower than −30°C until analysis. Postprandial
serum NEFA and TAG levels were measured at 0 (fasting),
60, 120, 180, 240, 300, 360, 420, and 480 min. Other
blood parameters were measured at fasting state. Assays
of serum NEFA, TAG, total cholesterol, low-density
lipoprotein cholesterol, high-density lipoprotein choles-
terol, insulin, amylase, total protein, alkaline phosphatase,aspartate aminotransferase, alanine aminotransferase, lac-
tase dehydrogenase, gamma-glutamyl transpeptidase, total
bilirubin, plasma glucose, and blood hemoglobin A1c
(HbA1c) levels were performed at BML (Bio Medical
Laboratories) Inc. (Tokyo, Japan). Serum apolipoprotein
B-48 (apo B-48) levels were determined using an ELISA
kit (AKHB48J, Shibayagi Co., Ltd., Gunma, Japan), in
accordance with the manufacturer’s instructions. Briefly,
sera diluted 500- or 1000-fold in the assay diluents were
added to microtiter wells coated with immobilized
anti-apo B-48 monoclonal antibody and incubated at
room temperature for 1 h. After washing with a washing
buffer, biotin-conjugated anti-apo B-48 was added to
each well and incubated with gentle shaking at room
temperature for 1 h. After the plate was washed, horserad-
ish peroxidase-conjugated avidin solution was added, and
the resultant solution was incubated at room temperature
for 30 min. After the plate was washed, chromogenic sub-
strate solution was added, and the resultant solution was
incubated at room temperature for 20 min. Finally, a stop
solution for the reaction was added, and then the absorb-
ance of 450 nm at each well was measured using a plate
reader.
Statistical analysis
The baseline characteristics of the subjects were expressed
as means with their standard deviations. Other data were
expressed as means with their standard errors. The incre-
mental area under the curve (iAUC) for NEFA and TAG
were calculated using the trapezoidal rule. Differences in
the amount of change between the control and active FM
periods were analyzed using a paired t test. Postprandial
serum TAG levels were determined by a one-sided test
because in our previous study, LG2055 inhibited the ab-
sorption of dietary TAG in rats, making it unnecessary to
consider lipid absorption enhancement [4]. The statistical
differences in the other parameters were analyzed by a
two-sided test. We considered a P < 0.05 to be statistically
significant.
Results
Effects of the active FM on the postprandial NEFA and
TAG levels
All the participants followed the study protocol without
difficulty. The postprandial responses of serum NEFA level
after the intake of the OFLT meals are shown in Figure 1a.
The serum NEFA levels showed a temporary downturn
from the baseline and then turned upward. Active FM
significantly decreased the postprandial serum NEFA levels
from 120 to 480 min after the intake of the OFLT meals
compared with the control FM (from 120 to 240 min,
P < 0.05; from 300 to 480 min, P < 0.01), leading to a signifi-
cantly lower NEFA-iAUC (P < 0.01). There was no signifi-
cant difference in NEFA-iAUC between males and females
Figure 1 The changes in the postprandial serum NEFA (a) and
TAG levels (b) in response to the oral fat-loading test (OFLT)
meal. The black circles indicate the level after the intake of the
control FM, and the white circles indicate the level after the intake
of active FM. The incremental areas under the curves (iAUC) are
shown as inserts. Values are expressed as mean (SE). *P< 0.05, **P< 0.01,
versus the control FM. Abbreviations: NEFA, non-esterified fatty acid; TAG,
triacylglycerol; FM, fermented milk.
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control FM period, respectively; 61.4 ± 12.1 mEq/min/l
and 75.8 ± 13.2 mEq/min/l in the active FM period,
respectively).
The postprandial responses of the serum TAGs are
illustrated in Figure 1b. When the subjects consumed
the OFLT meal, the serum TAG levels quickly increased
from the baseline (0 min) and reached their highest
levels at 240 min after the OFLT meal intake. In the
active FM period, the serum TAG level at 120 min after
the intake of the OFLT meals was significantly lower
(P < 0.05) than that in the control FM period. No signifi-
cant difference in TAG-iAUC was found between the
periods.Effects of the active FM on the anthropometric and
fasting blood parameters
The effects of the control and active FM preparations on
the anthropometric and fasting blood parameters are
listed in Table 2. None of the anthropometric parame-
ters showed statistically significant differences in changes
from W0 between the control and active FM periods.
Among the blood parameters, the value of change from
W0 in fasting serum NEFA level in the active FM period
significantly decreased (P < 0.001) compared with that in
the control FM period. There was no significant difference
in the value of change from W0 in fasting NEFA level be-
tween males and females (0.09 ± 0.05 mEq/l and 0.10 ±
0.07 mEq/l in the control FM period, respectively; −0.06 ±
0.04 mEq/l and −0.04 ± 0.01 mEq/l in the active FM
period, respectively). A significant difference (P = 0.002)
in the value of change from W0 in HbA1c level was ob-
served between the control and active FM periods, in
which the value was greater in the active period than in
the control period (Table 2), although these real values
were lower than 6.5% of the cutoff HbA1c level for dia-
betes diagnosis as recommended by the World Health
Organization [20]. No significant differences in the other
fasting serum parameters were found between the control
and active FM periods.
Daily life and adverse events
Irregularities in daily life or adverse events related to FM
consumption were not observed throughout the course
of the study, according to the daily record and interview
with the physician (data not shown).
Discussion
We investigated the postprandial lipid responses after an
OFLT meal intake in the subjects with hypertriacylgly-
cerolemia who ingested fermented milk with or without
LG2055 for 4 weeks. To our knowledge, this is the first
intervention study on OFLT in probiotics. The postpran-
dial serum NEFA levels from 120 to 480 min after OFLT
meal intake in the active FM period were significantly
lower than those in the control FM period (Figure 1a).
The postprandial serum TAG levels in the active FM
period tended to be lower from 60 to 180 min and sig-
nificantly lower at 120 min compared with the control
FM period (Figure 1b). This time point of 120 min cor-
responded to the time point when the postprandial
NEFA levels in the active FM period were still prevented
from increasing, whereas in the control FM period, the
NEFA levels already began to increase from the time
point of 60 min. We consider that this delayed onset of
the increase in the NEFA level in the active FM period
might lead to the subsequent lowered NEFA levels in the
active FM period compared with the control FM period.
Furthermore, the plateau level of the postprandial NEFA
Table 2 Anthropometric parameters and fasting levels of the blood parameters before and after the intake of control
or active FM
Parameters Period W0 W4 Change from W0 P value
Anthropometric parameters
Body weight Control 70.5 (2.4) 70.3 (2.4) −0.23 (0.26) 0.093
(kg) Active 70.7 (2.4) 70.6 (2.3) −0.04 (0.12)
BMI Control 24.5 (0.5) 24.4 (0.5) −0.09 (0.09) 0.512
(kg/m2) Active 24.5 (0.5) 24.5 (0.5) −0.01 (0.04)
Waist Control 87.4 (1.5) 85.6 (1.3) −1.78 (0.53) 0.461
(cm) Active 85.4 (1.5) 84.7 (1.4) −0.75 (0.35)
Blood parameters
TAG Control 246.5 (18.9) 272.4 (26.9) 25.9 (24.9) 0.528
(mg/dl) Active 268.3 (31.5) 273.4 (33.5) 5.2 (14.4)
NEFA Control 0.382 (0.033) 0.472 (0.034) 0.090 (0.037) 0.0003
(mEq/l) Active 0.399 (0.031) 0.344 (0.026) −0.056 (0.026)
Apo B-48 Control 9.38 (1.44) 9.98 (1.31) 0.59 (0.76) 0.173
(μg/ml) Active 10.24 (2.06) 9.25 (1.46) −0.98 (0.89)
Total cholesterol Control 215.7 (9.1) 220.5 (8.6) 4.8 (4.3) 0.797
(mg/dl) Active 214.1 (7.0) 217.2 (7.8) 3.1 (4.4)
LDL cholesterol Control 128.7 (8.3) 132.5 (7.1) 3.8 (4.0) 0.347
(mg/dl) Active 127.0 (7.0) 125.0 (7.3) −2.0 (3.4)
HDL cholesterol Control 43.5 (2.0) 43.4 (2.1) −0.2 (0.8) 0.504
(mg/dl) Active 43.6 (2.4) 42.4 (2.2) −1.2 (1.2)
Glucose Control 94.5 (2.0) 94.1 (2.0) −0.4 (1.0) 0.883
(mg/dl) Active 93.4 (2.6) 93.4 (2.0) 0.0 (1.9)
Insulin Control 9.01 (0.66) 8.60 (0.85) −0.41 (0.46) 0.998
(μU/ml) Active 10.63 (2.39) 10.22 (0.95) −0.41 (2.45)
Amylase Control 81.5 (8.3) 94.3 (21.1) 12.8 (14.5) 0.217
(U/l) Active 103.5 (21.4) 91.5 (15.3) −12.0 (8.6)
HbA1c Control 5.04 (0.04) 5.01 (0.05) −0.03 (0.03) 0.002
(%) Active 5.05 (0.05) 5.13 (0.05) 0.08 (0.01)
Total protein Control 7.05 (0.07) 7.14 (0.06) 0.09 (0.05) 0.192
(g/dl) Active 6.99 (0.07) 7.00 (0.07) 0.01 (0.04)
ALP Control 215.9 (13.0) 219.3 (13.5) 3.4 (4.6) 0.421
(U/l) Active 209.3 (12.3) 227.5 (20.8) 18.2 (16.2)
AST Control 20.8 (1.2) 20.7 (1.2) −0.1 (0.8) 0.974
(U/l) Active 21.0 (1.2) 21.0 (1.1) 0.0 (0.9)
ALT Control 24.8 (1.8) 24.2 (2.3) −0.6 (1.7) 0.674
(U/l) Active 23.2 (2.1) 23.9 (1.9) 0.7 (1.7)
LDH Control 159.9 (3.4) 159.3 (3.0) −0.6 (1.8) 0.055
(U/l) Active 154.4 (2.9) 161.2 (4.2) 6.8 (2.6)
γ-GTP Control 49.2 (7.5) 52.8 (7.0) 3.7 (3.0) 0.484
(U/l) Active 48.3 (7.1) 61.6 (17.3) 13.4 (12.3)
Total bilirubin Control 0.82 (0.09) 0.81 (0.06) −0.01 (0.06) 0.088
(mg/dl) Active 0.88 (0.06) 0.71 (0.06) −0.18 (0.04)
Abbreviations: TAG triacylglycerol, NEFA non-esterified fatty acid, Apo apolipoprotein, LDL low-density lipoprotein, HDL high-density lipoprotein, HbA1c hemoglobin
A1c, ALP alkaline phosphatase, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactase dehydrogenase, γ-GTP gamma-glutamyl transpeptidase.
The data are expressed as mean (SE) at each time point before (week 0, W0) and after (week 4, W4) intake of control or active FM (n = 20). A paired t test was
performed to compare the changes in the response to the control and active FM.
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360 min was significantly lower than that in the control
FM period at around the same time point; thus, we also
consider that the lower NEFA levels reflected the inhibited
increase in the TAG levels, which are primarily influenced
by the state of fat absorption.
Tan et al. [12] also reported that postprandial NEFA
levels from 120 to 240 min and postprandial TAG level
at 120 min after OFLT meal intake in diabetes subjects
treated with orlistat were significantly decreased com-
pared with those in subjects treated with a placebo. They
described that the decreased NEFA levels were generated
from the event that NEFA was not supplied from the
postprandial TAG owing to the suppression of fat ab-
sorption. This finding is consistent with our results and
suggests that the suppression of lipid absorption by
LG2055 may contribute to the significantly decreased
NEFA levels in this postprandial period. Inhibition of
pancreatic lipase can possibly suppress lipid absorption,
as it has recently been reported that two Lactobacilli
strains, viable Lactobacillus gasseri NLB367 [21] and
heat-killed Lactobacillus pentosus S-PT84 [22], inhibited
pancreatic lipase in vitro, although whether our LG2055
strain inhibits lipase activity has yet to be examined.
The postprandial serum NEFA levels after 240 min
(the late postprandial phase) in the active FM period
were significantly lower than those in the control FM
period, although the postprandial TAG levels during the
time did not differ between the control and active FM
periods. NEFA is known to be produced from the TAG
hydrolysis process by lipoprotein lipase to produce
NEFA and glycerol, which are incorporated into the
liver, muscles, and adipose tissues. In the present study,
TAG was likely to be equally hydrolyzed to generate the
same amount of NEFA, given that TAG levels did not
differ between the control and active FM periods after
240 min. However, difference in the ability to incorpor-
ate NEFA could cause the different NEFA levels between
the control and active FM periods; thus we consider that
the control FM period might less incorporate NEFA than
the active FM period. Such NEFA which is not incorpo-
rated and remaining in the bloodstream is known to be
crucial for the late postprandial rise in NEFA [23,24].
Ingestion of the anti-diabetic drug rosiglitazone, known
as a peroxisome proliferator-activated receptor (PPAR)-γ
agonist, was reported to significantly lower plasma NEFA
levels during the postprandial period and simultaneously
reduce plasma TAG levels from 240 to 360 min [25].
However, LG2055 did not affect serum TAG levels from
240 to 480 min (Figure 1b). Rosiglitazone ameliorates
blood glucose levels in diabetic subjects via the incorpor-
ation of some amount of blood glucose into the adipose
tissues, along with some amount of blood NEFA derived
from the TAG hydrolysate; this mechanism occasionallyleads to adverse effects such as increases in body fat mass
and body weight [26,27]. By contrast, while LG2055 inges-
tion decreased body fat mass and body weight in humans
[8,9], postprandial NEFA levels were also significantly low-
ered by LG2055 ingestion. Thus, the effects of LG2055 on
lipid metabolism may differ from those of the PPAR-γ
agonist.
Judging from the unchanged TAG-iAUC result, we
consider the magnitude of the fat absorption suppression
by LG2055 to be mild (Figure 1b). The mild suppression
may be due to the experimental condition we applied in
the present study. Although there are no official guide-
lines for the OFLT, recent studies performed OFLT using
a moderate (0.35-0.7 g of fat/kg body mass) rather than
a high-fat meal [28], and our study has also been carried
out within the moderate range (0.67 g of/kg body mass).
In addition to the amount of fat loading, other factors
such as racial differences greatly affect the postprandial
TAG response [29]. Therefore, we compared the experi-
mental condition of our study with that of other studies,
in which Japanese subjects were recruited and the effects
of functional food components on the postprandial TAG
levels were examined [30-32]. The amount of fat loading
was higher, and the high baseline fasting serum TAG
levels of our subjects, in comparison with those of other
studies. Other studies performed an OFLT and evaluated
the suppressive effects of functional food components
[30-32] at loading levels of 18.8 to 40 g of fat, whereas
our study was performed at a loading level of 47.2 g of
fat. In addition, the baseline fasting serum TAG levels of
the subjects in the other studies ranged from 144.5 to
175 mg/dl, whereas the mean baseline level in our study
was 277.0 mg/dl. These factors might lead to higher in-
creases in TAG after OFLT; the ΔTAG level was 231.2
mg/dl in our study, whereas it ranged from 61 to 130
mg/dl in the other reports. Thus, the great increase in
postprandial TAG levels in our study might have ob-
scured the suppressive effect of LG2055 on postprandial
TAG responses.
An elevation of blood TAG levels is a well recognized
cardiovascular risk factor [33]. We consider that lower-
ing NEFA levels is also beneficial for human health as
well as lowering TAG levels. Elevated NEFA levels are a
predictor of subsequent development of type 2 diabetes
[34], and associated with the deterioration of glucose
tolerance [35,36]. Dysregulation of plasma NEFA levels
is central to the insulin resistance and is associated with
dyslipidemia [37]. In the present study, a significant
decrease in fasting NEFA level at W4 from W0 was ob-
served in the active FM period (Table 2), which could be
a possible accumulated effect of the decrease in the post-
prandial NEFA levels (Figure 1a) over time. The ability
of LG2055 to continuously lower serum NEFA levels
may help reduce the risk for T2DM and obesity.
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in the value of change from W0 in HbA1c level was ob-
served between the active and control FM periods, in
which the value was greater in the active FM period than
in the control FM period (Table 2). Additionally, within-
period comparisons between W0 and W4 did not reveal
significant differences both in the control and in the ac-
tive FM periods (statistical symbols were not shown).
This observation is consistent with that reported by
Chang et al. [38]. They reported that blood HbA1c levels
tended to increase in healthy volunteers who consumed
a probiotic yogurt NY-YP901 for 8 weeks, whereas the
intake of placebo yogurt for 8 weeks tended to decrease
blood HbA1c levels.
Conclusions
In conclusion, the consumption of probiotic LG2055 re-
duced postprandial serum NEFA levels after the intake of
OFLT meals and fasting NEFA levels at the end of the
feeding period, suggesting its possible contribution to the
reduction of the risk for obesity and T2DM.
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